Display options
Cite
Crombie KM, Privratsky AA, Schomaker CM, et al. The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD. Neuroimage Clin. 2021;33:102922doi: 10.1016/j.nicl.2021.102922.
Crombie, K. M., Privratsky, A. A., Schomaker, C. M., Heilicher, M., Ross, M. C., Sartin-Tarm, A., Sellnow, K., Binder, E. B., Andrew James, G., & Cisler, J. M. (2021). The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD. NeuroImage. Clinical, 33102922. https://doi.org/10.1016/j.nicl.2021.102922
Crombie, Kevin M, et al. "The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD." NeuroImage. Clinical vol. 33 (2021): 102922. doi: https://doi.org/10.1016/j.nicl.2021.102922
Crombie KM, Privratsky AA, Schomaker CM, Heilicher M, Ross MC, Sartin-Tarm A, Sellnow K, Binder EB, Andrew James G, Cisler JM. The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD. Neuroimage Clin. 2021 Dec 20;33:102922. doi: 10.1016/j.nicl.2021.102922. Epub 2021 Dec 20. PMID: 34952353; PMCID: PMC8715233.
Copy Download .nbib Format: NLM
Share it on

Neuroimage Clin. 2021 Dec 20;33:102922. doi: 10.1016/j.nicl.2021.102922. Epub 2021 Dec 20.

The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD.

NeuroImage. Clinical

Kevin M Crombie, Anthony A Privratsky, Chloe M Schomaker, Mickela Heilicher, Marisa C Ross, Anneliis Sartin-Tarm, Kyrie Sellnow, Elisabeth B Binder, G Andrew James, Josh M Cisler

Affiliations

  1. The University of Texas at Austin, Department of Psychiatry and Behavioral Sciences, Health Discovery Building, 1601 Trinity St., Building B, Austin, TX 78712, USA. Electronic address: [email protected].
  2. University of Arkansas for Medical Sciences, Brain Imaging Research Center, 4301 W. Markham Street #554, Little Rock, AR 72205, USA.
  3. The University of Texas at Austin, Department of Psychiatry and Behavioral Sciences, Health Discovery Building, 1601 Trinity St., Building B, Austin, TX 78712, USA.
  4. University of Wisconsin - Madison, Department of Psychiatry, 6001 Research Park Boulevard, Madison, WI 53719-1176608-262-6375, USA.
  5. Max Planck Institute of Psychiatry, Department of Translational Psychiatry, Kraepelinstr. 2-10, 80804, Munchen, Germany; Emory University, Department of Psychiatry and Behavioral Sciences, 12 Executive Park Dr NE #200, Atlanta, GA 30329, USA.

PMID: 34952353 PMCID: PMC8715233 DOI: 10.1016/j.nicl.2021.102922

Abstract

BACKGROUND: Posttraumatic Stress Disorder (PTSD) is commonly treated with exposure-based cognitive therapies that are based on the principles of fear acquisition and extinction learning. Elevations in one of the major endocannabinoids (anandamide) either via inhibition of the primary degrading enzyme (fatty acid amide hydrolase; FAAH) or via a genetic variation in the FAAH gene (C385A; rs324420) has resulted in accelerated extinction learning and enhanced extinction recall among healthy adults. These results suggest that targeting FAAH may be a promising therapeutic approach for PTSD. However, these effects have not yet been comprehensively examined in a PTSD population.

METHODS: The current study examined whether genetic variation in the FAAH gene (CC [n = 49] vs AA/AC [n = 36] allele carriers) influences physiological (skin conductance), cognitive (threat expectancy), and neural (network and voxel-wise activation) indices of fear acquisition and extinction learning among a sample of adult women with PTSD (N = 85).

RESULTS: The physiological, cognitive, and neural signatures of fear acquisition and extinction learning varied as a function of whether or not individuals possess the FAAH C385A polymorphism. For instance, we report divergent responding between CC and AA/AC allele carriers to CS + vs CS- in limbic and striatum networks and overall greater activation throughout the task among AA/AC allele carriers in several regions [e.g., inferior frontal, middle frontal, parietal] that are highly consistent with a frontoparietal network involved in higher-order executive functions.

CONCLUSIONS: These results suggest that genetic variation within the FAAH gene influences physiological, cognitive, and neural signatures of fear learning in women with PTSD. In order to advance our understanding of the efficacy of FAAH inhibition as a treatment for PTSD, future clinical trials in this area should assess genetic variation in the FAAH gene in order to fully depict and differentiate the acute effects of a drug manipulation (FAAH inhibition) from more chronic (genetic) influences on fear extinction processes.

Copyright © 2021. Published by Elsevier Inc.

Keywords: Anandamide; Endocannabinoid system; Fatty acid amide hydrolase; Independent component analysis; Interpersonal violence; fMRI

References

  1. Depress Anxiety. 2021 Oct;38(10):1087-1099 - PubMed
  2. Neuropharmacology. 2005 Jun;48(8):1105-16 - PubMed
  3. J Consult Clin Psychol. 1993 Dec;61(6):984-91 - PubMed
  4. Mol Psychiatry. 2013 Jul;18(7):813-23 - PubMed
  5. Psychol Med. 2020 Jul;50(9):1442-1451 - PubMed
  6. Mol Psychiatry. 2016 Apr;21(4):500-8 - PubMed
  7. Biol Psychiatry. 2020 Mar 15;87(6):538-547 - PubMed
  8. Arch Gen Psychiatry. 1995 Dec;52(12):1048-60 - PubMed
  9. J Clin Psychiatry. 2018 Mar/Apr;79(2): - PubMed
  10. J Psychiatr Res. 2014 Jan;48(1):47-55 - PubMed
  11. PLoS One. 2009 Jun 10;4(6):e5865 - PubMed
  12. Psychol Violence. 2013 Jul;3(3):273-287 - PubMed
  13. Neuropharmacology. 2013 Jan;64:396-402 - PubMed
  14. Clin Psychol Rev. 2007 Jun;27(5):572-81 - PubMed
  15. Neuron. 2020 Mar 18;105(6):1077-1093.e7 - PubMed
  16. Neurobiol Learn Mem. 2014 Sep;113:125-34 - PubMed
  17. Sci Rep. 2020 Nov 16;10(1):19894 - PubMed
  18. Biol Psychiatry. 2009 Jul 1;66(1):9-16 - PubMed
  19. Neuropsychopharmacology. 2018 Jan;43(1):80-102 - PubMed
  20. Front Neurosci. 2013 Dec 10;7:237 - PubMed
  21. Ann N Y Acad Sci. 2003 Dec;1008:112-21 - PubMed
  22. J Neurosci Res. 2021 May 29;: - PubMed
  23. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6 - PubMed
  24. JAMA. 2007 Feb 28;297(8):820-30 - PubMed
  25. Neurosci Biobehav Rev. 2021 Nov 24;132:76-91 - PubMed
  26. Alcohol Clin Exp Res. 2016 Nov;40(11):2426-2434 - PubMed
  27. Arch Gen Psychiatry. 1998 Jul;55(7):626-32 - PubMed
  28. Transl Psychiatry. 2020 Aug 15;10(1):287 - PubMed
  29. Arch Gen Psychiatry. 2005 Jun;62(6):617-27 - PubMed
  30. Psychol Med. 2018 Jan;48(1):155-167 - PubMed
  31. J Neurosci. 2004 May 5;24(18):4393-400 - PubMed
  32. J Consult Clin Psychol. 2002 Aug;70(4):867-79 - PubMed
  33. J Neurosci. 2014 Oct 1;34(40):13435-43 - PubMed
  34. Sci Rep. 2021 Jan 19;11(1):1825 - PubMed
  35. Psychopharmacology (Berl). 2013 Dec;230(3):353-62 - PubMed
  36. J Psychiatry Neurosci. 2021 Mar 17;46(2):E238-E246 - PubMed
  37. Neuroscience. 1997 Mar;77(2):299-318 - PubMed
  38. Psychoneuroendocrinology. 2021 Oct;132:105355 - PubMed
  39. Mol Psychiatry. 2020 Oct;25(10):2342-2354 - PubMed
  40. JAMA Psychiatry. 2017 May 1;74(5):501-510 - PubMed
  41. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13040-5 - PubMed
  42. Eur J Psychotraumatol. 2017 Oct 27;8(sup5):1353383 - PubMed
  43. Neuroimage Clin. 2020;27:102319 - PubMed
  44. Nat Commun. 2015 Mar 03;6:6395 - PubMed
  45. Neuropsychopharmacology. 2018 May;43(6):1284-1296 - PubMed
  46. Biol Psychol. 2013 Dec;94(3):490-7 - PubMed
  47. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110118 - PubMed
  48. Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18333-8 - PubMed
  49. Nat Med. 2003 Jan;9(1):76-81 - PubMed
  50. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:124-140 - PubMed
  51. Mol Psychiatry. 2020 May;25(5):993-1005 - PubMed
  52. Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7900-5 - PubMed
  53. Cogn Behav Ther. 2018 Sep;47(5):351-371 - PubMed
  54. Behav Res Ther. 2020 Jun;129:103605 - PubMed
  55. Neurosci Biobehav Rev. 2018 May;88:16-25 - PubMed
  56. Psychol Assess. 2018 Mar;30(3):383-395 - PubMed
  57. Annu Rev Clin Psychol. 2013;9:215-48 - PubMed
  58. Annu Rev Neurosci. 2012;35:529-58 - PubMed
  59. Psychopharmacology (Berl). 2009 Jul;204(4):607-16 - PubMed
  60. Am J Hum Genet. 2007 Sep;81(3):559-75 - PubMed
  61. Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2428-36 - PubMed
  62. Trends Neurosci. 1990 Oct;13(10):420-3 - PubMed
  63. Behav Res Ther. 2020 Jan;124:103528 - PubMed
  64. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44 - PubMed
  65. Nature. 2002 Aug 1;418(6897):530-4 - PubMed
  66. Behav Res Ther. 2014 Jul;58:10-23 - PubMed
  67. Brain Topogr. 2021 Sep;34(5):598-607 - PubMed
  68. Biol Psychiatry. 2022 Feb 1;91(3):262-272 - PubMed
  69. Psychopharmacology (Berl). 2020 Jun;237(6):1813-1826 - PubMed
  70. Psychophysiology. 2018 Nov;55(11):e13214 - PubMed
  71. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8394-9 - PubMed
  72. Biol Psychiatry. 2018 Jul 15;84(2):129-137 - PubMed
  73. Neurosci Biobehav Rev. 2017 Jun;77:247-285 - PubMed
  74. Behav Res Ther. 2021 Jul;142:103867 - PubMed
  75. Transl Psychiatry. 2014 Jul 08;4:e408 - PubMed
  76. Biol Mood Anxiety Disord. 2013 Oct 22;3(1):19 - PubMed
  77. Trends Cogn Sci. 2019 Apr;23(4):274-277 - PubMed
  78. Behav Res Ther. 2008 Jan;46(1):5-27 - PubMed
  79. Philos Trans R Soc Lond B Biol Sci. 2008 Dec 12;363(1511):3787-800 - PubMed
  80. J Clin Psychiatry. 2017 Jul;78(7):e782-e789 - PubMed
  81. PLoS Comput Biol. 2018 Aug 31;14(8):e1006243 - PubMed

Publication Types